A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Biomarkers/*blood ; Brain Neoplasms/*blood ; Glioma/*blood ; MicroRNAs/*blood; Humans
    • Abstract:
      Glioma is the most common malignant intracranial tumour. Recently, several publications have suggested that miRNAs can be used as potential diagnostic biomarkers of glioma. Here we performed a meta-analysis to identify the diagnostic accuracy of differentially expressed circulating miRNAs in gliomas. Using PubMed, Medline and Cochrane databases, we searched for studies which evaluated a single or panel of miRNAs from circulating blood as potential biomarkers of glioma. Sixteen publications involving 23 studies of miRNAs from serum or plasma met our criteria and were included in this meta-analysis. The pooled diagnostic parameters were calculated by random effect models and overall diagnostic performance of altered miRNAs was illustrated by the summary receiver operator characteristic (SROC) curves. The pooled sensitivity, specificity, positive likelihood ratio (PLR) and negative likelihood ratio (NLR) from each study were calculated. The pooled PLR, NLR and Diagnostic Odds Ratio were 6.39 (95% CI, 4.61-8.87), 0.15 (95% CI, 0.11-0.21) and 41.91 (95% CI, 23.15-75.88), respectively. The pooled sensitivity, specificity and area under the curve (AUC) were 0.87 (95% CI, 0.82-0.91), 0.86 (95% CI, 0.82-0.90) and 0.93 (95% CI, 0.91-0.95), respectively. This meta-analysis demonstrated that circulating miRNAs are capable of distinguishing glioma from healthy controls. Circulating miRNAs are promising diagnostic biomarkers for glioma and can potentially be used as a non-invasive early detection.
    • References:
      Curr Genomics. 2015 Oct;16(5):304-11. (PMID: 27047250)
      J Neurochem. 2011 Aug;118(3):449-57. (PMID: 21561454)
      Lancet Neurol. 2010 Sep;9(9):906-20. (PMID: 20705518)
      Biochem Biophys Res Commun. 2009 Mar 6;380(2):205-10. (PMID: 19135980)
      PLoS One. 2012;7(3):e32709. (PMID: 22442669)
      Neuro Oncol. 2015 Mar;17(3):383-91. (PMID: 25140035)
      J Neurosurg. 2016 Oct;125(4):1008-1015. (PMID: 26799295)
      Cell Res. 2008 Oct;18(10):997-1006. (PMID: 18766170)
      Cancer Sci. 2010 Oct;101(10):2087-92. (PMID: 20624164)
      PLoS One. 2013 Jul 29;8(7):e69807. (PMID: 23922807)
      Ann Intern Med. 2011 Oct 18;155(8):529-36. (PMID: 22007046)
      Nat Methods. 2014 Aug;11(8):809-15. (PMID: 24973947)
      Neuro Oncol. 2014 Jul;16(7):896-913. (PMID: 24842956)
      Cancer Res. 2008 Aug 1;68(15):6416-24. (PMID: 18676867)
      Tumour Biol. 2016 Sep;37(9):11657-11665. (PMID: 27438704)
      Nature. 2005 Jun 9;435(7043):834-8. (PMID: 15944708)
      Mol Neurobiol. 2016 Jan;53(1):163-170. (PMID: 25416859)
      Neuro Oncol. 2014 Apr;16(4):520-7. (PMID: 24435880)
      J Neurosurg. 2016 Jan;124(1):122-8. (PMID: 26230475)
      Oncol Lett. 2016 Jan;11(1):904-908. (PMID: 26870304)
      Urol Oncol. 2010 Nov-Dec;28(6):655-61. (PMID: 19375957)
      Neurol Sci. 2015 Feb;36(2):309-13. (PMID: 25190548)
      J Clin Oncol. 2011 Dec 20;29(36):4781-8. (PMID: 22105822)
      Oncol Rep. 2013 Sep;30(3):1239-48. (PMID: 23835497)
      Int J Clin Exp Pathol. 2015 May 01;8(5):4943-52. (PMID: 26191187)
      Eur J Cancer. 2011 Mar;47(5):784-91. (PMID: 21112772)
      Int J Clin Exp Med. 2015 Jan 15;8(1):456-63. (PMID: 25785017)
      Cell. 2004 Jan 23;116(2):281-97. (PMID: 14744438)
      Med Sci Monit. 2016 Mar 15;22:855-62. (PMID: 26978735)
      Gynecol Oncol. 2008 Jul;110(1):13-21. (PMID: 18589210)
      Br J Cancer. 2015 Mar 31;112(7):1241-6. (PMID: 25756397)
      Nat Genet. 2016 Jul;48(7):768-76. (PMID: 27270107)
      Clin Lung Cancer. 2009 Jan;10(1):42-6. (PMID: 19289371)
      Ann Neurol. 2011 Jul;70(1):9-21. (PMID: 21786296)
      Cell Death Dis. 2014 Jun 05;5:e1279. (PMID: 24901050)
      Mol Neurobiol. 2015 Dec;52(3):1540-1546. (PMID: 25367878)
      AJNR Am J Neuroradiol. 2000 Aug;21(7):1213-9. (PMID: 10954271)
      Biochem Biophys Res Commun. 2014 Nov 7;454(1):210-4. (PMID: 25450382)
      Int J Cancer. 2013 Jan 1;132(1):116-27. (PMID: 22674182)
      Oncol Rep. 2014 Sep;32(3):957-64. (PMID: 25017996)
      J Exp Clin Cancer Res. 2012 Nov 22;31:97. (PMID: 23174013)
      Neuro Oncol. 2013 Sep;15(9):1212-24. (PMID: 23733246)
      ScientificWorldJournal. 2014 Jan 02;2014:178075. (PMID: 24516357)
      Mol Neurobiol. 2016 Apr;53(3):1452-1460. (PMID: 25636684)
      Tumour Biol. 2016 Feb;37(2):1407-10. (PMID: 26628296)
      J Exp Clin Cancer Res. 2016 Jul 30;35(1):124. (PMID: 27476114)
      Cancer Biomark. 2017;19(2):137-144. (PMID: 28211798)
      Cell. 2012 Mar 30;149(1):36-47. (PMID: 22464322)
      N Engl J Med. 2005 Mar 10;352(10 ):987-96. (PMID: 15758009)
    • Accession Number:
      0 (Biomarkers)
      0 (MicroRNAs)
    • Publication Date:
      Date Created: 20180215 Date Completed: 20180309 Latest Revision: 20181113
    • Publication Date:
      20240628
    • Accession Number:
      PMC5812551
    • Accession Number:
      10.1371/journal.pone.0189452
    • Accession Number:
      29444091